Image source: Getty Images
When it comes to building wealth in the share market, patience is often the most powerful tool and allows compounding to do its work.
While blue chips provide stability, adding a handful of high-quality ASX growth shares to your portfolio can help accelerate returns.
That’s because these companies often have the potential to grow their earnings faster than the market average, which can multiply the value of your investment over the years.
With that in mind, here are three explosive buy-rated ASX growth shares that could reward investors who are willing to hold for the next decade.
Life360 is best known for its family safety and location-sharing app, which has become a household name in markets like the United States. The ASX growth share has seen its user base and paying subscribers consistently climb at double-digit rates. So much so, at the end of June, global monthly active users had surged to around 88 million, up 25% year on year, while paying circles increased to 2.5 million.
With recurring subscription revenue growing strongly and average revenue per user also trending higher, Life360 is starting to show the kind of operating leverage that long-term investors love. And as it expands internationally and into other markets such as elderly and pet tracking, it still has a long growth runway ahead.
Morgan Stanley is bullish and has a buy rating and $58.50 price target on its shares.
Pro Medicus Ltd (ASX: PME)
Another ASX growth share that could be a strong contender for buy and hold investors is Pro Medicus. It is one of the most successful healthcare technology stories on the ASX.
Its Visage imaging software is used by hospitals and radiology groups to manage and interpret medical images with speed and accuracy. In recent years, Pro Medicus has won major contracts with leading healthcare providers in the US and Europe, cementing its reputation as a global leader in its niche.
What arguably makes Pro Medicus most attractive is its high-margin business model. The company enjoys recurring revenues through long-term contracts, and its software is mission-critical for customers, making it hard to replace. And with healthcare systems under pressure to improve efficiency and outcomes, demand for Pro Medicus’ solutions should remain strong over the next decade.
Citi recently put a buy rating and $350.00 price target on its shares.
Temple & Webster Group Ltd (ASX: TPW)
Finally, Temple & Webster could be an ASX growth share to buy and hold.
As the leading online furniture and homewares retailer in Australia, it is riding the structural shift to online shopping.
Ecommerce still makes up a relatively small slice of the furniture and homewares market compared to other regions, which means there is significant runway for growth. Temple & Webster has also been investing in technology, logistics, and private-label products, which should support its margins as it scales.
Macquarie thinks its shares have major upside potential and has put an outperform rating and $31.30 price target on them.